IP Library Granted Patent US 10,570,387
Granted Patent B2
US 10,570,387 · App. 15/846,602 · Granted Feb 25, 2020

Antigen screening system

Inventors: Jessica Flechtner (Sudbury, MA); Todd Gierahn (Brookline, MA)
Assignee: GENOCEA BIOSCIENCES, INC.
C12N15/1037C12Q1/025G01N33/5047G01N33/569
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,570,387
App. No.
15/846,602
Granted
Feb 25, 2020
Kind
B2
Abstract

Methods and compositions for identifying antigens of human lymphocytes are provided herein.

Claims (29)

1. A method of identifying an autoimmune antigen, the method comprising:

(a) providing a library comprising bacterial cells, wherein each bacterial cell of the library comprises a heterologous polypeptide expressed in a target cell or tissue of a human subject;

(b) contacting the bacterial cells with a first plurality of human cells which comprises human antigen presenting cells that internalize the bacterial cells;

(c) contacting the first plurality of human cells with a second plurality of human cells which comprises human lymphocytes, under conditions in which lymphocytes are stimulated by polypeptides presented by the first plurality of human cells;

(d) determining whether a lymphocyte of the second plurality of human cells is stimulated by a heterologous polypeptide presented by a cell of the first plurality of human cells, wherein stimulation of a lymphocyte of the second plurality of human cells by a heterologous polypeptide presented by a cell of the first plurality of human cells indicates that the heterologous polypeptide is an autoimmune antigen.

2. The method of claim 1 , wherein the first plurality of human cells is isolated from the human subject.

3. The method of claim 1 , wherein the bacterial cells further comprise a cytolysin polypeptide.

4. The method of claim 3 , wherein the cytolysin polypeptide is listeriolysin O (LLO).

5. The method of claim 1 , wherein the first plurality of human cells is provided in an array, and wherein cells in each location of the array are contacted with a set of bacterial cells, each set comprising a different heterologous polypeptide.

6. The method of claim 1 , wherein the first and second plurality of human cells comprise cells from peripheral blood.

7. The method of claim 1 , wherein the first plurality of human cells comprises dendritic cells.

8. The method of claim 1 , wherein the first plurality of human cells comprises immortalized cells.

9. The method of claim 1 , wherein the second plurality of human cells comprises human lymphocytes derived from a target cell or tissue of a human subject.

10. The method of claim 1 , further comprising formulating the antigen or a nucleic acid encoding the antigen as an immunogenic composition.

11. A method of identifying an autoimmune antigen, the method comprising:

(a) providing a library comprising bacterial cells, wherein each bacterial cell of the library comprises a heterologous polypeptide expressed in a target cell or tissue of a human subject;

(b) contacting the bacterial cells with a first plurality of human cells from one or more initial human subjects which comprises human antigen presenting cells that internalize the bacterial cells;

(c) contacting the first plurality of human cells with a second plurality of human cells from the one or more initial human subjects which comprises human lymphocytes, under conditions in which lymphocytes are stimulated by polypeptides presented by the first plurality of human cells;

(d) determining whether a lymphocyte of the second plurality of human cells is stimulated by a heterologous polypeptide presented by a cell of the first plurality of human cells, wherein stimulation of a lymphocyte of the second plurality of human cells by a heterologous polypeptide presented by a cell of the first plurality of human cells indicates that the heterologous polypeptide is an autoimmune antigen; and

(e) repeating steps (b) to (d) with human cells isolated from one or more additional human subjects, wherein the additional human subjects have different clinical manifestations of an autoimmune disorder than the one or more initial human subjects.

12. The method of claim 11 , wherein the first plurality of human cells is isolated from the human subject.

13. The method of claim 11 , wherein the bacterial cells further comprise a cytolysin polypeptide.

14. The method of claim 13 , wherein the cytolysin polypeptide is listeriolysin O (LLO).

15. The method of claim 11 , wherein the first plurality of human cells is provided in an array, and wherein cells in each location of the array are contacted with a set of bacterial cells, each set comprising a different heterologous polypeptide.

16. The method of claim 11 , wherein the first and second plurality of human cells comprise cells from peripheral blood.

17. The method of claim 11 , wherein the first plurality of human cells comprises dendritic cells.

18. The method of claim 11 , wherein the first plurality of human cells comprises immortalized cells.

19. The method of claim 11 , wherein the second plurality of human cells comprises human lymphocytes derived from a target cell or tissue of a human subject.

20. The method of claim 11 , further comprising formulating the antigen or a nucleic acid encoding the antigen as an immunogenic composition.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2022
From: GENOCEA BIOSCIENCES, INC.
To: ICHOR MEDICAL SYSTEMS, INC.
Reel/Frame 061418/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2017
From: FLECHTNER, JESSICA; GIERAHN, TODD
To: GENOCEA BIOSCIENCES, INC.
Reel/Frame 044433/0271 →
Continuity (5)
Division 14700573 · Apr 30, 2015
Continuation 13627332 · Sep 26, 2012
Continuation 12496171 · Jul 1, 2009
Provisional Application 61077323 · Jul 1, 2008
Related Publication 20180362966A1 · Dec 20, 2018